Wedbush Expects Increased Earnings for Ascendis Pharma A/S

Ascendis Pharma A/S (NASDAQ:ASND) – Equities researchers at Wedbush boosted their FY2029 EPS estimates for shares of Ascendis Pharma A/S in a research report issued on Wednesday, February 12th. Wedbush analyst Y. Zhong now anticipates that the biotechnology company will earn $14.13 per share for the year, up from their prior forecast of $13.76. Wedbush currently has a “Outperform” rating and a $181.00 target price on the stock. The consensus estimate for Ascendis Pharma A/S’s current full-year earnings is ($7.12) per share.

Ascendis Pharma A/S (NASDAQ:ASND) last released its earnings results on Wednesday, February 12th. The biotechnology company reported ($0.68) earnings per share for the quarter, beating analysts’ consensus estimates of ($1.32) by $0.64.

Other research analysts also recently issued reports about the stock. Oppenheimer reduced their target price on shares of Ascendis Pharma A/S from $190.00 to $180.00 and set an “outperform” rating for the company in a research report on Friday, November 15th. JPMorgan Chase & Co. raised their price objective on shares of Ascendis Pharma A/S from $167.00 to $168.00 and gave the stock an “overweight” rating in a report on Thursday. StockNews.com raised shares of Ascendis Pharma A/S from a “sell” rating to a “hold” rating in a report on Wednesday, November 20th. TD Cowen cut their price objective on shares of Ascendis Pharma A/S from $160.00 to $153.00 and set a “buy” rating for the company in a report on Friday, November 15th. Finally, The Goldman Sachs Group raised their price objective on shares of Ascendis Pharma A/S from $200.00 to $225.00 and gave the stock a “buy” rating in a report on Thursday. Two research analysts have rated the stock with a hold rating and thirteen have given a buy rating to the stock. According to data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and a consensus price target of $193.43.

Ascendis Pharma A/S Stock Up 1.1 %

Ascendis Pharma A/S stock opened at $144.08 on Friday. Ascendis Pharma A/S has a twelve month low of $111.09 and a twelve month high of $161.00. The firm has a 50 day moving average price of $132.41 and a 200-day moving average price of $132.36. The company has a market capitalization of $8.74 billion, a P/E ratio of -17.83 and a beta of 0.64.

Institutional Trading of Ascendis Pharma A/S

Several institutional investors and hedge funds have recently made changes to their positions in ASND. T. Rowe Price Investment Management Inc. raised its position in shares of Ascendis Pharma A/S by 54.4% during the 4th quarter. T. Rowe Price Investment Management Inc. now owns 2,725,546 shares of the biotechnology company’s stock valued at $375,226,000 after buying an additional 960,504 shares in the last quarter. Capital International Investors raised its position in shares of Ascendis Pharma A/S by 35.7% during the 4th quarter. Capital International Investors now owns 2,863,249 shares of the biotechnology company’s stock valued at $394,183,000 after buying an additional 753,859 shares in the last quarter. Groupama Asset Managment purchased a new stake in shares of Ascendis Pharma A/S during the 3rd quarter valued at $60,000. RA Capital Management L.P. raised its position in shares of Ascendis Pharma A/S by 4.1% during the 4th quarter. RA Capital Management L.P. now owns 10,112,744 shares of the biotechnology company’s stock valued at $1,392,221,000 after buying an additional 402,316 shares in the last quarter. Finally, Janus Henderson Group PLC raised its position in shares of Ascendis Pharma A/S by 6.8% during the 3rd quarter. Janus Henderson Group PLC now owns 4,186,694 shares of the biotechnology company’s stock valued at $625,075,000 after buying an additional 267,881 shares in the last quarter.

Ascendis Pharma A/S Company Profile

Ascendis Pharma A/S, a biopharmaceutical company, focuses on developing therapies for unmet medical needs. It offers SKYTROFA for treating patients with growth hormone deficiency (GHD). The company is also developing a pipeline of three independent endocrinology rare disease product candidates in clinical development, as well as focuses on advancing oncology therapeutic candidates.